Explore the impact of hypoxia-related genes (HRGs) in Cutaneous melanoma.

Publication date: Jul 08, 2023

Cutaneous melanoma (CM) has an overall poor prognosis due to a high rate of metastasis. This study aimed to explore the role of hypoxia-related genes (HRGs) in CM. We first used on-negative matrix factorization consensus clustering (NMF) to cluster CM samples and preliminarily analyzed the relationship of HRGs to CM prognosis and immune cell infiltration. Subsequently, we identified prognostic-related hub genes by univariate COX regression analysis and the least absolute shrinkage and selection operator (LASSO) and constructed a prognostic model. Finally, we calculated a risk score for patients with CM and investigated the relationship between the risk score and potential surrogate markers of response to immune checkpoint inhibitors (ICIs), such as TMB, IPS values, and TIDE scores. Through NMF clustering, we identified high expression of HRGs as a risk factor for the prognosis of CM patients, and at the same time, increased expression of HRGs also indicated a poorer immune microenvironment. Subsequently, we identified eight gene signatures (FBP1, NDRG1, GPI, IER3, B4GALNT2, BGN, PKP1, and EDN2) by LASSO regression analysis and constructed a prognostic model. Our study identifies the prognostic significance of hypoxia-related genes in melanoma and shows a novel eight-gene signature to predict the potential efficacy of ICIs.

Open Access PDF

Concepts Keywords
B4galnt2 Cutaneous melanoma (CM)
High Hypoxia
Infiltration ICIs


Type Source Name
disease MESH melanoma
pathway KEGG Melanoma
disease MESH metastasis
drug DRUGBANK Huperzine B
pathway REACTOME Reproduction
disease MESH tumor
disease MESH noma
drug DRUGBANK Nivolumab
disease MESH death
drug DRUGBANK Oxygen
drug DRUGBANK Coenzyme M
drug DRUGBANK Trestolone
drug DRUGBANK Saquinavir
disease MESH tumor immune evasion
drug DRUGBANK L-Valine
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK Hyaluronic acid
drug DRUGBANK Tropicamide
disease MESH acute myeloid leukemia
pathway KEGG Acute myeloid leukemia
disease MESH gastric cancers
drug DRUGBANK Tretamine
drug DRUGBANK Fructose
drug DRUGBANK Myricetin
pathway KEGG Ferroptosis
drug DRUGBANK Spinosad
drug DRUGBANK Bismuth subgallate
disease MESH clinical importance
pathway KEGG Gastric cancer
disease MESH Biliary Tract Cancer
drug DRUGBANK Gold
disease MESH hepatocellular carcinoma
pathway KEGG Hepatocellular carcinoma
drug DRUGBANK Carboxyamidotriazole
disease MESH prostate cancer
pathway KEGG Prostate cancer
drug DRUGBANK Guanosine
disease MESH uveal melanoma

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *